Literature DB >> 11106430

Dissection of the enzymatic and immunologic functions of macrophage migration inhibitory factor. Full immunologic activity of N-terminally truncated mutants.

R Kleemann1, H Rorsman, E Rosengren, R Mischke, N T Mai, J Bernhagen.   

Abstract

Macrophage migration inhibitory factor (MIF) is a cytokine with broad regulatory functions in innate immunity. MIF belongs to the few cytokines displaying catalytic activities, i.e. MIF has a Pro2-dependent tautomerase and a Cys-Ala-Leu-Cys (CALC) cysteine-based thiol-protein oxidoreductase activity. Previous studies have addressed the roles of the catalytic site residues and the C-terminus. The two activities have not been directly compared. Here we report on the N-terminal mutational analysis and minimization of MIF and on a dissection of the two catalytic activities by comparing mutants P2AMIF, Delta4MIF, Delta5MIF, Delta6MIF, Delta7MIF, Delta8MIF, and Delta10MIF with the cysteine mutants of MIF. As N-terminal deletion was predicted to interfere with protein structure due to disruption of the central beta sheet, it was surprising that deletion of up to six N-terminal residues resulted in normally expressed proteins with wild-type conformation. Strikingly, such mutants exhibited full MIF-specific immunologic activity. While mutation of Pro2 eliminated tautomerase activity, the CALC cysteine residues had no influence on this activity. However, mutant C81SMIF, which otherwise has full biologic activity, only had 32% tautomerase activity. Deletion of four N-terminal residues did not interfere with insulin reduction by MIF. By contrast, reduction of 2-hydroxyethyldisulfide (HED) was markedly affected by N-terminal manipulation, with P2AMIF and Delta2MIF exhibiting 40% activity, and Delta4MIF completely failing to reduce HED. This study constitutes the first comparison of the two catalytic activities of MIF and should assist in understanding the molecular links between the catalytic and immunologic activities of this cytokine and in providing guidelines for N-terminal protein minimization.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 11106430     DOI: 10.1046/j.1432-1327.2000.01823.x

Source DB:  PubMed          Journal:  Eur J Biochem        ISSN: 0014-2956


  16 in total

1.  Elevated levels of the Plasmodium yoelii homologue of macrophage migration inhibitory factor attenuate blood-stage malaria.

Authors:  Swati Thorat; Thomas M Daly; Lawrence W Bergman; James M Burns
Journal:  Infect Immun       Date:  2010-09-13       Impact factor: 3.441

2.  A novel allosteric inhibitor of macrophage migration inhibitory factor (MIF).

Authors:  Fengwei Bai; Oluwatoyin A Asojo; Pier Cirillo; Mihai Ciustea; Michel Ledizet; Paul A Aristoff; Lin Leng; Raymond A Koski; Thomas J Powell; Richard Bucala; Karen G Anthony
Journal:  J Biol Chem       Date:  2012-07-10       Impact factor: 5.157

3.  Activation of the JNK signalling pathway by macrophage migration inhibitory factor (MIF) and dependence on CXCR4 and CD74.

Authors:  Hongqi Lue; Manfred Dewor; Lin Leng; Richard Bucala; Jürgen Bernhagen
Journal:  Cell Signal       Date:  2010-08-31       Impact factor: 4.315

4.  Charge heterogeneity of bovine brain macrophage migration inhibitory factor.

Authors:  O A Cherepkova; E M Lutova; B Ya Gurvits
Journal:  Neurochem Res       Date:  2005-01       Impact factor: 3.996

5.  Direct modification of the proinflammatory cytokine macrophage migration inhibitory factor by dietary isothiocyanates.

Authors:  Kristin K Brown; Frances H Blaikie; Robin A J Smith; Joel D A Tyndall; Hongqi Lue; Jürgen Bernhagen; Christine C Winterbourn; Mark B Hampton
Journal:  J Biol Chem       Date:  2009-09-23       Impact factor: 5.157

6.  Structural determinants of MIF functions in CXCR2-mediated inflammatory and atherogenic leukocyte recruitment.

Authors:  Christian Weber; Sandra Kraemer; Maik Drechsler; Hongqi Lue; Rory R Koenen; Aphrodite Kapurniotu; Alma Zernecke; Jürgen Bernhagen
Journal:  Proc Natl Acad Sci U S A       Date:  2008-10-13       Impact factor: 11.205

7.  MIF deficiency reduces chronic inflammation in white adipose tissue and impairs the development of insulin resistance, glucose intolerance, and associated atherosclerotic disease.

Authors:  Lars Verschuren; Teake Kooistra; Jürgen Bernhagen; Peter J Voshol; D Margriet Ouwens; Marjan van Erk; Jitske de Vries-van der Weij; Lin Leng; J Hajo van Bockel; Ko Willems van Dijk; Günter Fingerle-Rowson; Rick Bucala; Robert Kleemann
Journal:  Circ Res       Date:  2009-05-28       Impact factor: 17.367

8.  Tumor-derived macrophage migration inhibitory factor (MIF) inhibits T lymphocyte activation.

Authors:  Xiaocai Yan; Rimas J Orentas; Bryon D Johnson
Journal:  Cytokine       Date:  2006-03-07       Impact factor: 3.861

9.  Ribosomal protein S19 interacts with macrophage migration inhibitory factor and attenuates its pro-inflammatory function.

Authors:  Ana-Maria Filip; Jörg Klug; Sevil Cayli; Suada Fröhlich; Tamara Henke; Philipp Lacher; Regina Eickhoff; Patrick Bulau; Monika Linder; Christine Carlsson-Skwirut; Lin Leng; Richard Bucala; Sandra Kraemer; Jürgen Bernhagen; Andreas Meinhardt
Journal:  J Biol Chem       Date:  2009-01-20       Impact factor: 5.157

Review 10.  Macrophage migration inhibitory factor: critical role in obesity, insulin resistance, and associated comorbidities.

Authors:  Robert Kleemann; Richard Bucala
Journal:  Mediators Inflamm       Date:  2010-02-09       Impact factor: 4.711

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.